Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


To Attack H1N1, Other Flu Viruses, Gold Nanorods Deliver Potent Payload

Joint research by UB and CDC could lead to new generation of antiviral medicines

Future pandemics of seasonal flu, H1N1 and other drug-resistant viruses may be thwarted by a potent, immune-boosting payload that is effectively delivered to cells by gold nanorods, report scientists at the University at Buffalo and the U.S. Centers for Disease Control and Prevention. The work is published in the current issue of the Proceedings of the National Academy of Sciences.

"This joint research by UB and the CDC has the potential to usher in a new generation of antiviral medicines to aggressively treat a broad range of infectious diseases, from H1N1 to avian flu and perhaps Ebola, that are becoming increasingly resistant to the medicines used against them," says UB team leader Paras Prasad, PhD, executive director of the UB Institute for Lasers, Photonics and Biophotonics (ILPB) and SUNY Distinguished Professor in the departments of Chemistry, Physics, Electrical Engineering and Medicine.

The collaborative work between UB and CDC came together through the work of Krishnan Chakravarthy, an MD/PhD candidate at UB and the paper's first author. This research constitutes part of his doctoral degree work that focused on host response to influenza infection and novel drug delivery strategies.

The paper describes the single strand RNA molecule, which prompts a strong immune response against the influenza virus by ramping up the host's cellular production of interferons, proteins that inhibit viral replication.

But, like most RNA molecules, they are unstable when delivered into cells. The gold nanorods produced at UB act as an efficient vehicle to deliver into cells the powerful immune activator molecule.

"It all boils down to how we can deliver the immune activator," says Suryaprakesh Sambhara, DVM, PhD, in CDC's Influenza Division and a co-author on the paper. "The UB researchers had an excellent delivery system. Dr. Prasad and his team are well-known for their contributions to nanoparticle delivery systems."

A key advantage is gold's biocompatibility.

"The gold nanorods protect the RNA from degrading once inside cells, while allowing for more selected targeting of cells," said co-author Paul R. Knight III, MD, Chakravarthy's thesis advisor; professor of anesthesiology, microbiology and infectious diseases in the UB School of Medicine and Biomedical Sciences; and director of its MD/PhD program.

"This work demonstrates that the modulation of host response is going to be critical to the next generation of anti-viral therapies," Chakravarthy explains. "The novelty of this approach is that most of these kinds of RNA viruses share a common host-response immune pathway; that is what we have targeted with our nanoparticle therapy. By enhancing the host immune response, we avoid the difficulty of ongoing viral resistance generated through mutations."

Diseases that could be effectively targeted with this new approach include any viruses that are susceptible to the innate immune response that type 1 interferons trigger, Prasad notes.

Based on these in vitro results, the UB and CDC researchers are beginning animal studies.

"This collaboration has been extraordinary as two disparate research groups at UB and a third at the CDC have managed to maintain progress toward a common goal: treatment of influenza," says co-author Adela Bonoiu, PhD, UB research assistant professor at ILPB.

Important funding for the UB institute portion of the research was provided by the John R. Oishei Foundation, which helped pave the way for new stimulus funding UB received recently from the National Institutes of Health to further develop this strategy. The goal is to work toward an Investigational New Drug filing with the FDA.

Additional funding was provided by the NIH, the Air Force Office of Scientific Research and the National Vaccine Program Office of the U.S. Department of Health and Human Services.

Co-authors are Earl J. Bergey, PhD, UB research associate professor of chemistry; Hong Ding, PhD, postdoctoral associate, and Rui Hu, formerly a visiting researcher of UB's ILPB, and William Davis, Priya Ranjan, J. Bowzard and Jacqueline M. Katz of the Influenza Division of the CDC.

Ellen Goldbaum | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht ‘Farming’ bacteria to boost growth in the oceans
24.10.2016 | Max-Planck-Institut für marine Mikrobiologie

nachricht Calcium Induces Chronic Lung Infections
24.10.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Oasis of life in the ice-covered central Arctic

24.10.2016 | Earth Sciences

‘Farming’ bacteria to boost growth in the oceans

24.10.2016 | Life Sciences

Light-driven atomic rotations excite magnetic waves

24.10.2016 | Physics and Astronomy

More VideoLinks >>>